Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Summary

Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.

Timeline

Start

2023-04-18

Primary completion

2025-12-23

Completion

2025-12-23

Publications

• Swenson CE, Hunt WR, Manfredi C, Beltran DJ, Hong JS, Davis BR, Suzuki S, Barilla C, Rab A, Chico C, Dangerfield J, Streby A, Barton E, Cox EM, Stecenko AA, Westbrook A, Kapolka R, Sorscher EJ. Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol. PLoS One. 2025 Feb 14;20(2):e0316721. doi: 10.1371/journal.pone.0316721. eCollection 2025.

Drugs

Indications